STEP-1
The Phase 3 trials that won approval, and the outcome studies that came afterward on cardiovascular, kidney and sleep-apnea endpoints.
What is STEP-1?
Semaglutide 2.4 mg weekly against placebo, the main phase 3 trial, run across 1,961 participants carrying excess weight (Wilding et al., NEJM 2021, PMID 33567185).
Average loss reached 14.9% by week 68. Nearly every piece of semaglutide marketing you encounter rests on that figure, compounded products included, though none of those were in the trial.
Read more:
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.
Where STEP-1 comes up on this site
On GLP Watchdog, STEP-1 comes up in 4 tools.
Tools that use it
Other terms under Major trials
Where the evidence lives
- The full GLP-1 glossary (150 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers